Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 397 trials

Acute Myeloid Leukemia: RVU120 with Venetoclax

We are studying a new treatment combining RVU120 and Venetoclax for patients with acute myeloid leukemia who did not respond to earlier therapies. The goal is to assess its safety and effectiveness in improving their condition.

Acute Myeloid Leukemia6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Postoperative Recovery: Spinal Morphine vs. Intravenous Lidocaine

We are studying if adding spinal morphine to pain management helps patients recover better after robotic-assisted upper urinary tract surgery. The goal is to see if it reduces pain and speeds up recovery compared to standard treatment.

Kidney and Ureter Disorders6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineNephrologyOncologyOtolaryngologyUrology

Melanoma: Ipilimumab and Nivolumab Combination

We are testing a new treatment using two immunotherapy drugs for patients with high-risk stage II melanoma. The goal is to see if this combination can improve outcomes before surgery.

Stage II Melanoma6-12 monthsEfficacy phase (II)DermatologyOncology

Cervical Cancer: ITHACA Immunotherapy Study

We are investigating the safety and immune effects of a new immunotherapy for early-stage cervical cancer. This study aims to understand how well this treatment works when delivered near the tumor.

Cervical Cancer6-12 monthsSafety phase (I)Gynecology and ObstetricsOncology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Weight Management in Schizophrenia: Semaglutide Study

We are investigating whether semaglutide can help patients with schizophrenia and obesity improve their weight and metabolic health. This study compares semaglutide to a placebo to see its effects on various health measures.

Metabolic Control in Antipsychotic-Using Patients6-12 monthsConfirmation phase (III)>20 visitsInvestigational MedicinesEndocrinologyPsychiatry

Atopic Dermatitis: Personalized Treatment Approaches

We are studying how genetic and biochemical markers can help choose the best treatment for patients with atopic dermatitis needing stronger therapies. This research may lead to better management strategies tailored to individual needs.

Atopic Dermatitis6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Chronic Spontaneous Urticaria: Omalizumab Treatment Intervals

We are studying whether adults with well-controlled chronic spontaneous urticaria can safely extend the time between omalizumab treatments while maintaining symptom control.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

Rectal Cancer Treatment: Comparing Therapies for Older Patients

We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.

Rectal Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

Lung Cancer6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Glioblastoma Treatment: Lomustine and Temozolomide Study

We are studying whether a combination of lomustine and temozolomide improves survival for newly diagnosed glioblastoma patients with a specific genetic marker. This trial also looks at side effects and quality of life compared to standard treatment.

Glioblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurologyOncology

Generalized Myasthenia Gravis: Iptacopan Study

We are studying a new treatment called iptacopan for people with generalized Myasthenia Gravis to see if it helps improve daily activities and muscle strength. The trial will also assess the safety of this treatment compared to a placebo.

AChR Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Cirrhosis Treatment: Albumin and Enoxaparin Study

We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.

Cirrhosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Plaque Psoriasis: ESK-001 Treatment Study

We are testing a new medication, ESK-001, for people with moderate to severe plaque psoriasis. The study aims to see if it works better than a placebo and an existing treatment.

Moderate to Severe Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology